News Release

Shareholder Tools

AmerisourceBergen Completes Public Offering of $400 Million 4.875% Senior Notes Due 2019

CHESTERBROOK, Pa.--(BUSINESS WIRE)--Nov. 19, 2009--
AmerisourceBergen Corporation (NYSE: ABC) today announced it had
completed its public offering of $400 million principal amount of 4.875%
Senior Notes due November 15, 2019. AmerisourceBergen intends to use
approximately $221.9 million of the net proceeds from this offering to
repay substantially all the amounts outstanding under its multi-currency
revolving credit facility. The remainder of the proceeds will be used
for general corporate purposes.

About AmerisourceBergen

AmerisourceBergen is one of the world's largest pharmaceutical services
companies with operations primarily in the United States, Canada.
Servicing both healthcare providers and pharmaceutical manufacturers in
the pharmaceutical supply channel, the Company provides drug
distribution and related services designed to reduce costs and improve
patient outcomes. AmerisourceBergen's service solutions range from
pharmacy automation and pharmaceutical packaging to reimbursement and
pharmaceutical consulting services. With more than $71 billion in annual
revenue, AmerisourceBergen is headquartered in Valley Forge, PA, and
employs approximately 10,000 people. AmerisourceBergen is ranked #26 on
the Fortune 500 list.

Forward-Looking Statements

This news release contains forward-looking statements about
AmerisourceBergen’s future business and financial performance, estimates
and prospects. These statements are based on management’s current
expectations and are subject to uncertainty and changes in
circumstances. Actual results may vary materially from the expectations
contained in the forward-looking statements. The following factors,
among others, could cause actual results to differ materially from those
described in any forward-looking statements: changes in pharmaceutical
market growth rates; the loss of one or more key customer or supplier
relationships; changes in customer mix; customer delinquencies, defaults
or insolvencies; supplier defaults or insolvencies; changes in
pharmaceutical manufacturers’ pricing and distribution policies or
practices; adverse resolution of any contract or other dispute with
customers or suppliers; federal and state government enforcement
initiatives to detect and prevent suspicious orders of controlled
substances and the diversion of controlled substances; qui tom
litigation for alleged violation of laws and regulations governing the
marketing, sale and purchase of pharmaceutical products; changes in U.S.
legislation or regulatory action affecting pharmaceutical product
pricing or reimbursement policies, including under Medicaid and
Medicare; changes in regulatory or clinical medical guidelines and/or
labeling for the pharmaceuticals we distribute, including certain anemia
products; price inflation in branded pharmaceuticals and price deflation
in generics; significant breakdown or interruption of our information
technology systems; our inability to implement an enterprise resource
planning (ERP) system to handle business and financial processes within
AmerisourceBergen Drug Corporation’s operations and our corporate
functions without operating problems and/or cost overruns; success of
integration, restructuring or systems initiatives; interest rate and
foreign currency exchange rate fluctuations; economic, business,
competitive and/or regulatory developments in Canada, the United Kingdom
and elsewhere outside of the United States, including potential changes
in Canadian provincial legislation affecting pharmaceutical product
pricing or service fees or regulatory action by provincial authorities
in Canada to lower pharmaceutical product pricing or service fees; the
impact of divestitures or the acquisition of businesses that do not
perform as we expect or that are difficult for us to integrate or
control; our inability to successfully complete any other transaction
that we may wish to pursue from time to time; changes in tax legislation
or adverse resolution of challenges to our tax positions; increased
costs of maintaining, or reductions in our ability to maintain, adequate
liquidity and financing sources; continued volatility, and further
deterioration of the capital and credit markets; and other economic,
business, competitive, legal, tax, regulatory and/or operational factors
affecting our business generally.Our most recent annual report
on Form 10-K, quarterly reports on Forms 10-Q and current reports 8-K
(which we may revise or supplement in future reports filed to the SEC)
provide additional information about these risks, uncertainties and
other matters. We do not undertake to update our forward-looking
statements.

Corporate Overview

AmerisourceBergen is one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. With services ranging from drug distribution and niche premium logistics to reimbursement and pharmaceutical consulting services, AmerisourceBergen delivers innovative programs and solutions across the pharmaceutical supply channel.